Dr. Jonathan Wang is a Senior Managing Director, Asia at OrbiMed. He has co-founded OrbiMed Asia and is a general partner at its venture capital fund. Previously, he was a Partner at Legend Capital and General Manager at Burrill Greater China Group. He also worked for WI Harper Group and Walden International, two pioneers in the Asia-related VC industry. At WI Harper, he was a Managing Director, overseeing the firm's life sciences activities worldwide.
He was a Board Director at ForteBio, Inc. (acquired by Pall Corporation) and was a co-founder and Board Director at Bridge Laboratories (acquired by Pharmaron Holdings Limited). He is a Board Director at EA, Inc. (formerly Chairman), Response Biomedical Corp. and Bonovo Orthopedics, Inc. He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.
Dr. Barbara Kinnaird has over 25 years of research and business experience primarily in the fields of point of care (POC) testing and in vitro diagnostics. Since joining Response Biomedical Corp. in August 2004, Dr. Kinnaird has held several key management positions including responsibilities for Product Development, Quality, Regulatory, Manufacturing and Sales. Dr. Kinnaird has consistently demonstrated her ability to deliver results from her areas of responsibility.
During Dr. Kinnaird’s tenure in these positions, she has lead teams to improve the product design control, operational efficiencies, gross margins and sales. Additionally under her direction, the Company obtained and maintain regulatory approvals to support sales in several global jurisdictions such as China, Japan, United States and Canada. Dr. Kinnaird’s strengths include her extensive experience in empowering a team to manage through organizational changes that improve the Company processes, decrease costs and accelerate business performance.
Dr. Kinnaird holds a Ph.D. in Microbiology and Immunology from the University of British Columbia at the B.C. Children’s Hospital in the Department of Pediatrics. She conducted her post-doctoral research at the Michael Smith Laboratories in genomics and gene expression profiling, in collaboration with the B.C. Genome Sciences Centre and consulted for the Proteomics division of Incyte Genomics Inc.
Mr. Liu Hui is the Chairman of Shanghai Runda Medical Technology Co. Ltd.
Ms. Caroline Chan is the Chief Marketing Officer of Shanghai Runda Medical Technology Co. Ltd.
Mr. Ken Xu is an Associate on the Asia team of OrbiMed focusing on the investment in healthcare. Prior to joining OrbiMed, he worked at Frost & Sullivan in Shanghai where he led and participated in consulting projects solving a wide spectrum of challenges faced by leading medical device companies and helping many local healthcare companies to list overseas.
Previously, he worked for KPMG Huazhen where he provided audit services to a variety of Hong Kong listed companies and multinational groups. Mr. Xu holds a M.S in Biochemistry and Molecular Biology and a B.S in Biotechnology from Shanghai Jiao Tong University.